CTX.TO (Mkap C$ 7.7 M) 1x FDA approved /2x Phase 3 und weitere Produkte am Markt (Seite 6)

[wandstrasse-ch]

Hallo zusammen.
Bin erstaunt, dass sich seit Februar der Kurs halbiert hat. Sind Gründe bekannt? Habe selbst nichts gefunden. Corona alleine kann kaum der Anlass dazu sein. Mit den aktuellen Zahlen müsste trotz Corona-Krise der Kurs ganz woanders stehen und der jetzige Kurs wäre eigentlich eine gute Einstiegsgelegenheit.

In den letzten zwei Tagen wurde ebenfalls mit eher überdurchschnittlichem Volumen abverkauft. Gibt es dafür einen Grund oder sind das einfach nur einzelne Anleger, die sich von ihrer Position getrennt haben (was bei low-floatern bekanntlich schnell Auswirkungen auf den Kurs hat)?

[kelev_ra]

So, die Tage mal alles an Stücken abgegriffen, was zu holen war Firma ist rentabel, und die Bewertung ein absoluter Witz.

[Jim_Panse]

Events Subsequent to December 31, 2019

On February 11, 2020, the Company announced positive topline results from two pivotal Phase 3 clinical trials for CTX-101 (formerly MiCal 1), an ultra-potent topical corticosteroid product being developed in partnership, for the treatment of plaque psoriasis using the Company's patented MMPE technology;

On January 24, 2020, the Company announced that its wholly-owned subsidiary, INTEGA Skin Sciences Inc. ("INTEGA") was awarded a cannabis research license by Health Canada under the Cannabis Act and Cannabis Regulations, allowing the Company to possess cannabis for the purpose of R&D;

On January 22, 2020, the Company announced that it had secured a $3,500 revolving demand operating credit facility (the "Facility") with a Canadian chartered bank;

On January 20, 2020, the Company announced that it had entered into a distribution agreement with Laboratoires FILLMED ("FILLMED" and the "FILLMED Agreement") for the exclusive distribution of the ART-FILLER® range of injectables and the New Cellular Treatment Factor® ("NCTF®") in Canada.

[Jim_Panse]

F2019 Corporate Developments

On December 20, the Company repaid in full its outstanding long-term debt with Knight Therapeutics Inc. (the "Knight Loan") in the amount of $3,570;
On November 5, the Company announced that the U.S. Food and Drug Administration ("FDA") approved an enhanced formulation of Pliaglis for the U.S., triggering a milestone payment of $988 ($US750) under its out-licensing agreement with Taro Pharmaceuticals Inc. ("Taro" and the "Taro Agreement");
On October 28, the Company announced a development and licensing agreement granting Sundial Growers Inc. ("Sundial" and the "Sundial Agreement") worldwide rights to the Company's proprietary transdermal delivery technologies, MMPE™ and DuraPeel™, for the development of topical products containing cannabis and/or hemp;
On July 16, the Company announced that the United States Patent and Trademark Office granted U.S. Patent No. 10,350,180 for an enhanced formulation of Pliaglis providing extended patent protection to 2031;
On June 28, the Company commenced a Normal Course Issuer Bid ("NCIB") to repurchase up to one million common shares for cancellation over a twelve-month period. During the year, the Company repurchased for cancellation 283,423 shares for total consideration of $257;
On May 15, the Company announced the launch of Dermazulene™ in China, a brand specifically designed and created for the Chinese market, including anti-aging, whitening and anti-pollution formulas. Products are distributed through NetEase Kaola, a leading cross-border import e-commerce platform in China;
On April 25, the Company announced that it entered into a commercialization license agreement with Cantabria Labs ("Cantabria and the "Cantabria Agreement"), granting Cantabria the exclusive rights to sell and distribute Pliaglis in Italy, Portugal, France, and Spain. Effective April 1st, the Company reacquired the rest-of-world ("ROW") rights to Pliaglis from Galderma S.A. In F2019, the Company recognized $5,459 in revenue from an up-front payment of $3,721 and $1,738 in guaranteed minimum royalties related to the Cantabria Agreement.

[Jim_Panse]

Ach übrigens...

Crescita Reports Q4 and Fiscal 2019 Results
Record Annual Revenue of $22.3M
Record Adjusted EBITDA of $7.0M up from $1.5M

LAVAL, QC, March 18, 2020 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX OTC) (US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development ("R&D") and manufacturing capabilities, today reported its financial results for the fourth quarter ("Q4-F2019") and fiscal year ended December 31, 2019 ("F2019").

Crescita Therapeutics Inc. (CNW Group/Crescita Therapeutics Inc.)

All amounts are in thousands of Canadian dollars except for share and per share amounts, unless otherwise noted.

Year-over-year Financial Highlights

F2019 vs. F2018

Record revenue of $22,337, an increase of $5,709 or 34.3%;
Recognized $5,459 in up-front payments and guaranteed future minimum royalties related to the out-licensing agreement with Cantabria Labs (see below);
Recognized $2,645 (US$2,000) in sales milestones from Taro related to the achievement of the final cumulative targets for the U.S. sales of Pliaglis®;
Recognized a development milestone of $988 (US$750) from Taro related to the approval of an enhanced formulation of Pliaglis by the FDA (defined below);
Operating expenses of $17,369, an increase of $704 or 4.2%;
Record Adjusted EBITDA1 of $6,984, an improvement of $5,533 versus $1,451;
Repaid the Knight Loan in full in the amount of $3,570 (see below);
Generated $4,249 in cash before repayment of the Knight Loan, resulting in closing cash position of $9,268 compared to $8,598 at the end of 2018.
Q4-F2019 vs. Q4-F2018

Q4-F2019 revenue of $3,820, a decrease of $2,384 or 38.4%;
Q4-F2019 revenue included a development milestone of $988 and $31 on the global net sales of Pliaglis – See Revenue below; Q4-F2018 revenue included $1,982 in sales and development milestones and $1,343 in royalties on the global net sales of Pliaglis;
Operating expenses of $4,406, a decrease of $446 or 9.2%;
Adjusted EBITDA1 of $6, a decrease of $1,773.
"I am proud of the results the Crescita team delivered in fiscal 2019 with record revenues and Adjusted EBITDA. We had some tailwinds during the year which added significantly to our top and bottom line growth, and we also proved that we could deliver organic growth through geographic expansion when we launched our first brand in China," said Serge Verreault, President and CEO of Crescita. "Over the last year, we were successful in laying the groundwork for growth platforms that we believe will generate revenues in 2020 and beyond. We continue to be guided by our strategic growth pillars as we work to add sustainable recurring revenue."

Mr. Verreault added, "While we expect quarterly revenue and profitability fluctuations throughout 2020 depending on the scale and timing of milestone and royalty revenue from our out-licensing partners, we continue to build Crescita for the long term by focusing on sustainable growth."

http://crescitatherapeutics.mediaroom.com/2020-03-18-Crescit…

[BTRRR]

Antwort auf Beitrag Nr.: 62.906.124 von Niller84 am 06.03.20 13:13:03

Bei Swissquote steht das, bei News!

[Niller84]

Antwort auf Beitrag Nr.: 62.859.843 von BTRRR am 03.03.20 08:12:07

Wo hast du das gelesen?
Kann aber gut hinkommen, letztes Jahr kamen die Zahlen am 20.03, sprich in 2-3 Wochen sollte sehr realistisch sein! Übrigens hält sich die Aktie außerordentlich stabil in diesen panikgeprägten Zeiten :-)

[BTRRR]

So wie ich es gelesen habe, kommen die Zahlen am 25.03.2020 stimmt das?

[julfi]

Antwort auf Beitrag Nr.: 62.856.051 von Biohero am 02.03.20 19:38:24

gibts hierzu einen link mit dem orderbuch? hab für tsx leider die realtime daten nicht abonniert.

[julfi]

Antwort auf Beitrag Nr.: 62.856.051 von Biohero am 02.03.20 19:38:24

sieht gut aus bin dabei